Deutsche Bank maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and raised its price target to $156.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data June 18, 2015 10:03 AM BioMarin (BMRN) PT Lifted to 'Street High' $170 at SunTrust Amid Growing Confidence in Dwarfism Drug BMN 111June 18, 2015 7:51 AM BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC June 18, 2015 7:35 AM BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 UpdateJune 18, 2015 7:02 AM BioMarin (BMRN) PT Raised to $143 at Leerink Partners as BMN-111 Meets Primary EndpointJune 18, 2015 6:28 AM BioMarin Pharma (BMRN) Issues Positive Update from BMN 111 Phase 2 Proof-of-Concept, Dose Finding StudyJune 17, 2015 4:05 PM BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 StudyJune 17, 2015 4:01 PM